Genzyme did a small trial using the AGTC AAV platform.
Dr. Jeff Heier ran the study.
(Genzyme was formerly a partner of AGTC but no longer)
Dr. Heier has a few of those patients out over four years with no re-treatment.
So the AGTC platform is at least proven in some cases.
(The study was written up in Retinal Physician a while back but you'll have to look for it in the archives if you want to check it out).
I believe Drs. Jean Bennett and Al Maguire (ONCE) have some long-term successful patients as well.
I have talked to top docs in gene therapy for retinal diseases.
Mainly at ONCE and AGTC,
These are basically the people who cured the Briard pups about 15 years ago and now have gone on to human trials.
There are examples of long-term successes using ONCE and AGTC adeno-associated virus (AAV) platforms. Some patients out 4 to 6 years with no need for re-treatment.
Even the so-called "failure" at AAVL met the study endpoints though it was a poorly designed trial.
Recent successful gene therapy trial by QURE has been totally ignored in the overall market meltdown.
Gene therapy is here to stay -- "curing" disease with a single injection is transformative and will save the healthcare system huge money by eliminating some "chronic" diseases.
Clearly, it will take some time.
I look at QURE at $20 a share -- why are people paying $4 for the January 30 call?
Why is AGTC trading for $13 when the company has $12 a share in cash and no debt?
Might be some real values there if you look beyond the next couple of months.
I think there is a growing feeling that stem cell therapy will "cure"
blindness or that gene therapy will do it.
That's very simplistic and uninformed.
Every case is different -- there is room for a lot of approaches.
EYES is essentially an attempt to turn a humanitarian effort into a commercial enterprise, which is not all that easy.
As far as the management goes, it is stellar.
As far as the IP, it is also far and away the leader.
From what I hear, the other prosthetic device developers are having problems with salt-water intrusion, which can short out the device after a couple of months -- must be heartbreaking for the patients.
EYES really not much of a takeover candidate.
I have to agree that news will drive any future gains -- and the company tends to announce good news
Need to get more devices implanted -- if that's a manufacturing issue it has to be a priority.
AGTC has $215 million in cash -- most came from Biogen deal.
The stock is trading for its cash in the bank -- that's a pretty good reason for owning the stock.
QURE proved that gene therapy works in humans -- yet all gene therapy stocks got clobbered.
Don't give up on AGTC.
ITEK has a clear path to FDA approval.
Company could sell international rights at any time for at least $200 million.
Trabodenoson also could be a neuroprotective -- more value.
Bottom should come in next month.
This is no time to give up on ITEK.
Without the FDA's intervention on changing the trial endpoint AERI is a $10 stock.
It's clear the FDA wants new glaucoma medications approved so the FDA has made it easy for AERI and ITEK to get their drugs approved.
So now that AERI has exploded, the next logical beneficiary of the FDA's largesse is ITEK.
Anakem is private and European, so not so well known.
But they are well into phase 2 in their US clinical trial.
Like AERI, Anakem has a ROCK category glaucoma drug.
It does not cause eye redness -- as Anakem is quick to emphasize.
True, Anakem is a bit behind AERI in terms of a projected approval date.
You have to factor Anakem into the equation.
Anakem is also European company -- so it flies under the radar of US investors.
Anakem trials show no eye redness.
It is also a ROCK drug -- so direct competition to AERI.
I like ITEK on any dip -- if no dip ITEK may fly.
When someone mentions that Anakem may have a better new glaucoma drug than AERI I will start taking this board seriously. Anakem drug -- no eye redness.
You are right about that.
All this data was previously available.
And the combination data is out there for 10 days. -- read your journals.
As others have said, not that great and totally predictable after all that came out previously, including
British Journal article.
ITEK on a dip is the better buy in my opinion.
AERI also has Anakem drug to deal with -- no eye redness problem with Anakem.
Lots of clueless buyers AH.
Totally predictable AERI data.
I see nothing that great here.
The British Journal of Ophthalmology reported that the combination was effective -- so big deal.
This jump is excessive in my opinion.
I like ITEK better -- especially at 12.50
Yes, that, too.
Neuroprotection is a huge deal.
It is the key to combating glaucoma and Alzheimer's, ALS and Parkinsons.
Glaucoma docs are trying flaxseed oil and gingko biloba as possible neuroprotectives.
That is just a shot in the dark.
If trabodenoson proves neuroprotective, the ceiling for the stock is much higher.
FDA approval is now baked in this cake.
International rights to trabodenoson will spark a bidding war.
I believe ITEK is woefully underpriced.
The drop to 11.50 was a second chance to get in, I think.
I am usually pretty conservative but this one is just too inviting.
AERI is not a rival -- only in the minds of the clueless.
New glaucoma medications are needed -- that is plural — more than one.
The FDA knows this and is making it easy for both ITEK and AERI.
I would put odds of ITEK success at 95 percent.
There's some new AERI data reported in British Journal of Ophthalmology. The combination is effective.
ITEK can sell international rights today for hundreds of millions.
Valeant recently bought into EYEG and SURG -- definitely a lot going on in the sector.
I am more into ITEK than anything else -- clear path to approval for novel glaucoma drug.
Liking EYES but it will be a long haul -- let's get some more Medicare coverage and set up some more international licensees.
Twenty implants per quarter -- that number must go up.
Don't see a buyout -- EYES is still more of a humanitarian effort than a commercial venture, but it is handling the transition well.
Valeant is on an acquisition binge in ophthalmic sector but EYES does not really figure for them.
Animal studies are animal studies -- don't really move the needle.
Expanded medicare reimbursement is important -- that could help the stock.
Get the implants up to 50-100 per quarter would help.